Dr. San Miguel on Pembrolizumab With Lenalidomide/ Dexamethasone in Multiple Myeloma
December 8th 2015Jesus San Miguel, MD, PhD, professor of Hematology, medical director of the ClÃnica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain, discusses the Keynote-023 study, which examined pembrolizumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.
Read More